May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
VEGF RNA Aptamer Binding Specificity and Inhibition of Ligand binding to VEGF Receptors in vitro
Author Affiliations & Notes
  • E. Ng
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • D. Krilleke
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • A. De Erkenez
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • L. Mullin
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • G. Robinson
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • A.P. Adamis
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • D.T. Shima
    Research, Eyetech Pharmaceuticals, Woburn, MA
  • Footnotes
    Commercial Relationships  E. Ng, Eyetech Pharmaceuticals E; D. Krilleke, Eyetech Pharmaceuticals E; A. De Erkenez, Eyetech Pharmaceuticals E; L. Mullin, Eyetech Pharmaceuticals E; G. Robinson, Eyetech Pharmaceuticals E; A.P. Adamis, Eyetech Pharmaceuticals E; D.T. Shima, Eyetech Pharmaceuticals E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1794. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Ng, D. Krilleke, A. De Erkenez, L. Mullin, G. Robinson, A.P. Adamis, D.T. Shima; VEGF RNA Aptamer Binding Specificity and Inhibition of Ligand binding to VEGF Receptors in vitro . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1794.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:MacugenTM (pegaptanib sodium) is a pegylated RNA aptamer that binds to and blocks VEGF165 function with high specificity and potency. The aim of this study was to determine the binding specificity of MacugenTM with regard to the different VEGF isoforms, and to members of the VEGF family that are homologous to VEGF165. We also examined aptamer inhibition of VEGF165 binding to its three high affinity receptors: KDR, Flt–1, and neuropilin–1 (Npn–1) in vitro. The inhibitory profile (IC50) of MacugenTM in a VEGF bioassay in HUVECs was examined. Methods:The target ligand binding affinities (KD) of the VEGF RNA aptamer were determined using a modified filter binding assay using serially diluted growth factors and a constant amount of radio–labeled aptamer. Binding of the aptamer to the VEGF188 isoform was examined using a Far–Western method where radio–labeled aptamer was used to detect re–natured VEGF188 protein immobilized on a membrane. Inhibition of I125–VEGF165 binding to VEGF receptor/Fc fusion proteins in the presence MacugenTM was examined using a plate–binding assay. Data from the binding assays were analyzed by non–linear regression. The IC50 of MacugenTM in an assay measuring VEGF–induced tissue factor (TF) expression in HUVEC was determined using real–time quantitative RT–PCR (TaqMan). Results: The VEGF aptamer exhibited high–affinity specific binding (KD of 70 to 100 pM) for VEGF165, however, did not bind VEGF121. Far–Western analysis suggests the aptamer binds less efficiently to VEGF188. The VEGF aptamer did not bind to the other VEGF family members tested (i.e., VEGF–B167, VEGF–C, PDGF–BB, PlGF). MacugenTM (pegylated VEGF aptamer) potently inhibited the binding of VEGF165 to all three of its receptors (i.e., VEGF–R1, VEGF –R2, Npn–1) in vitro with low nM potency. MacugenTM also inhibited VEGF–induced tissue factor expression with an IC50 in the low nM range. Conclusions: The VEGF RNA aptamer is a high affinity, highly–specific inhibitor of the heparin–binding VEGF isoform, VEGF165. MacugenTM ’s specificity, and potent inhibition of VEGF receptor binding and bioactivity strongly support its use as a therapeutic in the treatment of ocular neovascular conditions.

Keywords: age–related macular degeneration • pharmacology • neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.